title: Management of febrile neutropenia in the United Kingdom: time for a national trial?
abstract: Recent advances in febrile neutropenia (FN) have highlighted the value of risk stratification and the evolving role of oral antibiotics with early hospital discharge in low-risk patients. The aim of this study was to survey whether these advances have been translated into routine clinical practice in the UK. Questionnaires were sent to cancer clinicians across the UK to determine clinicians' routine management of FN, including use of risk stratification, antibiotic regimen and criteria for hospital discharge. In all, 128 clinicians responded, representing 50 cancer departments (83%). Only 38% of respondents stratify patients according to risk and with substantial variation in the criteria defining 'low-risk'. Furthermore, only 22% of clinicians use oral antibiotics as first-line treatment in any patients with FN, but this was significantly greater among clinicians who do compared to those who do not stratify patients by risk, 51 vs 4% (P<0.0001). These findings suggest a slow and/or cautious introduction of newer strategies for the management of low-risk FN in the UK. However, 84% of respondents confirmed their willingness to participate in a trial of oral antibiotics combined with early discharge in low-risk FN.
authors.affiliation: Clatterbridge Centre for Oncology, Bebington, Wirral, Merseyside CH63 4JY, UK.
authors.forename: H
authors.initials: H
authors.lastname: Innes
authors.forename: L
authors.initials: L
authors.lastname: Billingham
authors.forename: C
authors.initials: C
authors.lastname: Gaunt
authors.forename: N
authors.initials: N
authors.lastname: Steven
authors.forename: E
authors.initials: E
authors.lastname: Marshall
mesh_terms: D000284:Administration, Oral; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D005334:Fever / Q000188:drug therapy* / Q000209:etiology; D019538:Health Care Surveys; D006801:Humans; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy; D009503:Neutropenia / Q000188:drug therapy* / Q000209:etiology; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D018570:Risk Assessment; D006113:United Kingdom
chemical_list: D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents